Jacqueline V. Aredo

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

March, 2025

Jacqueline V. Aredo

Sep 24, 2024, 13:32 | Insight

Jarushka Naidoo: Stage III ALK+ NSCLC - consolidation ALK TKI vs Durvalumab vs Observation

Jarushka Naidoo shared on X: "Stage III ALK+ NSCLC: consolidation ALK Tyrosine Kinase Inhibitors versus…

Jul 21, 2024, 13:36 | Blog

Rami Manochakian: Neoadjuvant osimertinib in stage I-IIIA EGFRm NSCLC did not meet primary endpoint

Rami Manochakian shared a post on X: ''Hot off the press. Neoadjuvant Osimertinib for the…

All: 2 Posts: 1 - 100

'

Karen Knudsen has been appointed as the CEO of the Parker Institute for Cancer Immunotherapy

'

Highlights from ELCC 2025

'

FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer

'

Meet the New AACR Board of Directores for 2025-2028 Term

'

Do Artificial Sweeteners Cause Cancer? Myths and Facts

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023